Fuchs' Dystrophy is a progressive eye disease affecting the cornea's endothelial cells. As these cells deteriorate, fluid accumulates in the cornea, leading to swelling and vision problems. Symptoms include blurred vision, light sensitivity, and eye discomfort. Diagnosis involves eye examinations and specialized tests. While the exact cause is unknown, genetic factors, age, and gender play roles. Treatment options range from eye drops to corneal transplant surgery. Ongoing research focuses on understanding genetic factors, improving surgical techniques, and developing new treatments. Clinical trials are essential for advancing Fuchs' Dystrophy research and can be found through various resources.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...